Roche Investor Update: Roche Analyst Event at ASCO 2013 Donnerstag, 02. Mai 2013 - 10:10
Roche Analyst Event at ASCO 2013 Analyst briefing on data presented at ASCO: Sunday, 2 June 2013
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (31 May – 4 June 2013).
Venue Marriott Downtown Chicago 540 North Michigan Avenue 60611 Chicago
Date/Time Sunday, 2 June 2013 6:30pm to 8:00pm Central Daylight Time CDT (Chicago) followed by a buffet reception
Agenda • Obinutuzumab (GA101): Final stage 1 results of the CLL11 (BO21004) phase III trial • Oncology pipeline update • Oncology business and strategy update
Meeting information Date: 2 June 2013
Time: 6:00pm CDT Registration desk opens 6:30pm CDT Start of meeting 8:00pm CDT End of meeting followed by a buffet reception
To register for the event, please follow the link.
About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visitwww.roche.com.
All trademarks used or mentioned in this release are protected by law.
With best regards,
Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Luís Correia Ph.D. Phone: +41 61 68-75284 e-mail: luis.correia@roche.com
Tamer Farhan Ph.D. Phone: +41 61 68-82552 e-mail: tamer.farhan@roche.com
Dr. Nina Mojas Phone: +41 61 68-71300 e-mail: nina.mojas@roche.com
Elhan Webb, CFA Phone: +41 61 68-89630 e-mail: elhan.webb@roche.com
Investor Relations North America
Thomas Kudsk Larsen Phone: +1 650 467 2016 e-mail: larsen.thomas@gene.com
Nina Goworek Phone: +1 650 467 8737 e-mail: goworek.nina@gene.com
Ekaterine Kortkhonjia Ph.D. Phone: +1 650 467 5873 e-mail: kortkhonjia.ekaterine@gene.com